President's Message 

September, 2025

 

Dear All, 

 

As we head into fall, I wanted to share some exciting updates from the CIS leadership retreat. In July, the CIS Council met at our home office in Milwaukee to discuss our society's future. We left the retreat with a renewed drive to work toward our goals and continue supporting our community and field. Below, you'll find some photos from the event that capture our spirit, along with new key initiatives and general announcements. I hope you're enjoying the fall weather wherever you are reading this!

 

 

 

 

 

 

New Committee: Genetics and Genomics Committee

 

At the CIS Leadership Retreat, it became clear that to address critical gaps in the field of genetically-driven immune disease, we needed to create a Genetics and Genomics Committee. This action-oriented group will focus on identifying and improving our current resources and tools for advanced phenotyping, data processing, and data analysis.

We're excited to announce that Dr. Xiao Peng and Dr. Sebastian Ochoa Gonzalez will chair this new committee. We'll be posting more information on the CIS website soon.

 

 

Our society gains strong new leadership with Dr. Lisa Forbes Satter as President-Elect and Dr. Manish Butte as an elected Councilor. Their expertise will serve to continue the positive impact of the CIS. Additionally, we are excited to have the continued wisdom of Dr. Dan Adelman, who will continue in an appointed Councilor position for two years to enhance our knowledge of CIS’s financial outlook into the future alongside CIS Treasurer, Dr. Monica Lawrence. We are honored as well to welcome back Dr. Megan Cooper to the Council, where she will fill a one-year appointed vacancy following Dr. Monica Lawrence’s transition into the role of Treasurer. Dr. Cooper’s return is a tremendous asset to our organization, particularly given her deep familiarity with the developments surrounding the new official journal of CIS, the Journal of Human Immunity. Her expertise will be instrumental in keeping CIS members informed about key opportunities through JHI, both in the immediate future as well as in the years ahead.

 

 

 

The CIS-Grifols AIM Program will soon be accepting applications for a unique clinical and industry-based career development opportunity

CIS excels in the development and delivery of educational opportunities. The CIS Council decided to also embark on a new kind of educational and career development opportunity in partnership with Grifols. In today’s evolving therapeutic evaluation landscape, Industry collaborations have become an increasingly vital avenue for advancing innovation that drives meaningful improvements in patient outcomes.  To empower attendees to successfully navigate and leverage these opportunities, the CIS–Grifols AIM Program is proud to present a dynamic Clinical-Industry-Career Development Workshop this January 15-18, 2026 at the Hyatt Regency Lost Pines Resort in Austin, TX—designed to deliver actionable insights into industry collaboration strategies and foster professional growth.  

By participating in the CIS-Grifols AIM Program you will: 
  • Enhance Professional Skills
  • Master Industry Collaboration   
  • Incubate Your Ideas with a Shark Tank-Style “Immunovate” Experience   
  • Explore Career Pathways  

 

Interested and excited to shape the future of immunology? Call for applications coming soon!

 

 

 

New Opportunity to Connect

 

CIS is now on Bluesky! CIS understands the importance of staying connected and disseminating knowledge amongst our membership. Bluesky is a great platform for sharing the latest research in our field. Please Join us there by following @clinimmsoc. If you have a paper you think we should promote, email info@clinimmsoc.org.

You can also follow us on multiple social media platforms.  Connect today!

 

 

 

 

Unique New Job Announcement and CIS Job Board

A unique opportunity with the Immune Deficiency Foundation has become available. The IDF is searching for an in-house Medical Director to provide strategy, guidance, and expertise on matters related to immune deficiency and shape strategic directions. Information about this position and others can be found on the CIS Job Board.

 

The CIS Job Board reaches the CIS community and beyond! Whether you are looking to fill a position, or looking for the next step in your career, we hope you start here!

 

 

 

If you would like your opportunity included in a newsletter, please email mhanan@clinimmsoc.org for review and consideration by the CIS leadership.

 

 

New USIDNET Registry

I would like to take a moment to highlight the transformative work that the USIDNET is currently doing. They have revolutionized the way Registry Research is performed in the IEI space. The USIDNET launched a new independent registry database that utilizes semi-automated data extraction as the sole source of data collection, avoiding countless hours of manual data entry and essentially eliminating human entry error. This results in 'Bigger, Faster, and Better Data Collection'.

CIS recently sent out a brief survey to membership to gather critical stakeholder feedback on potential future USIDNET resources. Thank you to all members who completed the survey. The results will be included in a pending NIH funding application to illustrate how critical this resource is to our community.

To learn more about the new USIDNET Registry and how to get involved or conduct a registry study visit United States Immunodeficiency Network (https://usidnet.net). The previous registry data is also still available for query by visiting the old website at https://usidnet.org.

St. Jude's Children's Research Hospital Seeking Study Sites

Investigators at St. Jude Children's Research Hospital are seeking sites interested in participating in a prospective, Phase II, non-randomized, single arm clinical trial to estimate the efficacy of a response-adapted regimen incorporating ruxolitinib, dexamethasone, and etoposide for the treatment of children and young adults with newly diagnosed hemophagocytic lymphohistiocytosis (HLH).

If you are interested in potentially participating, please contact Kim Nichols, MD at Kim.nichols@stjude.org.

Newly Open Clinical Trial for X-linked CGD

CIS realizes the challenges faced in the development of gene therapy for patients with IEI. A new Phase 1/2 trial of an in vivo approach to gene therapy for X-linked CGD is now open.

You can learn more and read the eligibility criteria at https://clinicaltrials.gov/study/NCT06876363.

 

The Clinical Immunology Society remains steadfast in its commitment to advancing our field and supporting every member of our community. Your voice is vital to this mission, and we encourage you to actively engage with us. Please never hesitate to reach out to me or any member of the CIS leadership with your ideas, concerns, or aspirations; we are here to listen and to serve as your partners in progress.

 

Warmly,

 

Rebecca Marsh, MD, FCIS

CIS President

 

 

top